ARIA News Alert Ariad Pharmaceuticals (ARIA) 5.39 09/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ariad Pharmaceuticals (ARIA) 5.39 $ARIA

Amgen Files Blinatumomab Marketing Application in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 4:55PM CDT
Amgen (AMGN) announced that it has submitted a Biologics License Application to the FDA for blinatumomab.

Ariad Director Resignation May Mean CEO Berger One Step Closer to Exit
at The Street - Fri Sep 19, 11:05AM CDT
Activist investor Alex Denner is gaining an ally on Ariad's Board.,

INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US

Why Ariad Pharmaceuticals, Inc. Stock Plunged 11% in 2014
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 08, 1:10PM CDT
All things considered, it's been a relatively calm year for Ariad Pharmaceuticals shareholders after their stock went cliff-diving in October of last year. With its shares down 11% year-to-date stakeholders probably aren't happy, but compared to...

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte
at The Street - Fri Sep 05, 7:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.

Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:

'Mad Money' Lightning Round: Yahoo! Is One of the Best Buys Around
at The Street - Thu Sep 04, 5:00AM CDT
Cramer likes Araid Pharmaceuticals and Occidental Petroleum and is sticking with his Taser recommendation.

Jim Cramer's 'Mad Money' Recap: These Are 3 Stocks Cramer Trusts
at The Street - Wed Sep 03, 7:17PM CDT
Cramer wants Apple, Microsoft and Dow Chemical on his team.

Ariad Pharmaceuticals Rises 4.50% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Aug 26, 4:26PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.12 to a high of $6.65. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $6.25 on volume of 14.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Why Ariad Pharmaceuticals (ARIA) Stock Is Up Today
at The Street - Tue Aug 26, 11:36AM CDT
Ariad Pharmaceuticals (ARIA) rose Tuesday as Roche's $8.3 billion acquisition of InterMune (ITMN) has led the biotech sector higher.

5 Stocks Insiders Love Right Now
at The Street - Thu Aug 21, 1:11PM CDT
Insiders at these companies have been scooping up shares of their own stock lately.

Look for Shares of Ariad Pharmaceuticals to Potentially Pullback after Yesterday's 2.90% Rise
Comtex SmarTrend(R) - Tue Aug 12, 5:00PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $5.48 to a high of $5.79. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $5.63 on volume of 5.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

ARIAD Falls on Wider-than-Expected Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:21AM CDT
ARIAD (ARIA) reported a loss of 30 cents per share in the second quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 27 cents.

11.6% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Fri Aug 08, 10:00AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 1 month, Ariad Pharmaceuticals has returned 11.62% as of today's recent price of $5.36.

ARIAD Reports Second Quarter 2014 Financial Results and Development Progress
Business Wire - Wed Aug 06, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2014, including revenue from sales of Iclusig(R) (ponatinib). The Company also provided an update on corporate developments.

Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 3:45PM CDT
GW Pharmaceuticals (GWPH) is scheduled to report third-quarter fiscal 2014 results on Aug 6.

Should You Sell Ariad Pharmaceuticals (ARIA) Before Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 7:48AM CDT
Ariad Pharmaceuticals (ARIA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform the market.

ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel
Business Wire - Tue Aug 05, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that ARIAD has granted Medison exclusive rights to commercialize Iclusig(R) (ponatinib) in Israel in patients with Philadelphia-positive (Ph+) leukemias.

The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics
PR Newswire - Fri Aug 01, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA-Free Report), ImmunoGen, Inc. (Nasdaq:IMGN-Free Report) and Durata Therapeutics, Inc. (Nasdaq RTX-Free Report).

Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 175

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 34

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 115

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 16

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 211

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 0

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
Teen Adoption Campaign Makes Room for Mutual Growth

Updated Category News Views 120

A bicycle wobble and a ballet count carry more weight than they first appear to. The new Adoption from Foster Care public service ads put teens in the instructor's spot: a son helps his mother learn to ride a bike in Two Wheeler, while a daughter walks her father through ballet in Routine. It is a small creative reversal, but a smart one. Teen adoption is too often framed...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 77

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 0

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading

Top 5 Most Recently Viewed Articles

A.B. Data Appoints Steve Straub as New Operations VP

Updated Category News Views 542

A.B. Data Appoints Steve Straub as New Operations VP A.B. Data, a prominent name in class action notice and claims administration, has elevated Steve Straub to the role of Vice President of Operations. Having served as the Senior Director of Operations since 2023, Steve brings a wealth of experience that will further strengthen the company’s operations. Strategic...

Continue Reading
Conexon Connect Expands Fiber Network for Rural Internet Access

Updated Category News Views 170

Conexon Connect's Milestone Achievement Conexon Connect has successfully completed a transformative fiber-to-the-home (FTTH) project, expanding high-speed internet access to over 12,000 members of rural electric cooperatives. This expansive network marks a significant achievement in bridging the digital divide, particularly for underserved communities. Partnerships...

Continue Reading
Xiaomi MIX Flip 2 Unveils TCL CSOT's Cutting-Edge Displays

Updated Category News Views 349

TCL CSOT Powers the Xiaomi MIX Flip 2's Display Experience TCL CSOT is making waves in the tech world by providing state-of-the-art displays for the Xiaomi MIX Flip 2. This new foldable smartphone marks a significant shift in user experiences, aligning perfectly with the growing demand for portable, high-performance devices. During a recent launch event showcasing...

Continue Reading
Immunic Showcases Promising Results for Vidofludimus Calcium

Updated Category News Views 106

Immunic Highlights Key Findings from CALLIPER Trial Immunic, Inc. (Nasdaq: IMUX), a leading biotechnology company specializing in innovative oral therapies for neurologic and gastrointestinal conditions, recently presented significant data from its Phase 2 CALLIPER trial. This trial evaluates its cornerstone therapy, vidofludimus calcium (IMU-838), aimed at treating...

Continue Reading
Amrop Expands Global Reach with New Office in Colombia

Updated Category News Views 153

Amrop Expands With a New Office in Colombia Amrop, a distinguished global executive search and leadership consulting firm, has recently announced the establishment of a new office in Colombia. This expansion marks a significant milestone for Amrop as they enhance their service offerings in Latin America. Introducing Amrop Colombia Amrop Colombia emerges from the merger...

Continue Reading